Genetics of therapy-related myelodysplasia and acute myeloid leukemia (Q37058777)

18 August 2017

1 reference

title

Genetics of therapy-related myelodysplasia and acute myeloid leukemia (English)

1 reference

18 August 2017

1 reference

J Pedersen-Bjergaard

1

1 reference

18 August 2017

M K Andersen

series ordinal

2

1 reference

18 August 2017

M T Andersen

series ordinal

3

1 reference

18 August 2017

D H Christiansen

series ordinal

4

1 reference

18 August 2017

publication date

17 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

22

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

240-248

1 reference

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Oncogenic Transcription Factors in the Human Acute Leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Chromatin structural elements and chromosomal translocations in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Genetics of myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported i

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Implications of NRAS mutations in AML: a study of 2502 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

The myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Establishment and characterization of a megakaryoblast cell line with amplification of MLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Population-based demographic study of karyotypes in 1709 patients with adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor progno

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Activating mutations of JAK2V617F are uncommon in t-MDS and t-AML and are only observed in atypic cases

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.LEU.2405078

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2405078

1 reference

18 August 2017

1 reference